Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04438083 |
| Title | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | CRISPR Therapeutics AG |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | NLD | CAN | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Research Site 2 | Duarte | California | 91010 | United States | Details | |
| Research Site 5 | Hartford | Connecticut | 06520 | United States | Details | |
| Research Site 4 | Houston | Texas | 77030 | United States | Details | |
| Research Site 3 | Salt Lake City | Utah | 84112 | United States | Details | |
| Research Site 1 | Melbourne | Victoria | 3000 | Australia | Details | |
| Research Site 6 | Toronto | Ontario | M5G 2M9 | Canada | Details | |
| Research Site 7 | Amsterdam | North Holland | 1066 | Netherlands | Details |